Barinthus (BRNS) merges with Clywedog; Clywedog stockholders to own ~66% of combined company

Barinthus Biotherapeutics plc.

Clywedog stockholders will receive ~4.36 Topco shares per Clywedog share; Barinthus shareholders receive 1 Topco share per share.
Clywedog stockholders to own ~66% of combined entity; Barinthus shareholders ~34%.
Topco may launch self-tender offer for up to $27M of its common stock prior to Merger close.
Deal expected to close in H1 2026, subject to shareholder approvals, court sanction, antitrust clearance, and Nasdaq listing.
Voting agreements cover ~25% of Barinthus shares and all Clywedog shares; lock-ups for six months for certain insiders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.